Johnson & Johnson (NYSE:JNJ) has been assigned a consensus rating of “Hold” from the twenty-two ratings firms that are presently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $146.02.

A number of research analysts recently commented on JNJ shares. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Monday, January 22nd. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Wells Fargo & Co reaffirmed an “outperform” rating and set a $160.00 price objective (up from $155.00) on shares of Johnson & Johnson in a research report on Friday, January 12th. Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Finally, JPMorgan Chase & Co. downgraded shares of Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd.

How to Become a New Pot Stock Millionaire

Shares of Johnson & Johnson (NYSE:JNJ) traded down $2.02 on Friday, reaching $132.33. 3,262,000 shares of the company were exchanged, compared to its average volume of 8,266,445. Johnson & Johnson has a 52-week low of $120.95 and a 52-week high of $148.32. The stock has a market capitalization of $359,310.00, a P/E ratio of 24.58, a PEG ratio of 2.17 and a beta of 0.77. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, beating the Zacks’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The firm had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. During the same period in the previous year, the firm posted $1.58 earnings per share. The firm’s revenue was up 11.5% on a year-over-year basis. equities analysts predict that Johnson & Johnson will post 8.11 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th were paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date of this dividend was Monday, February 26th. Johnson & Johnson’s payout ratio is 61.88%.

In other news, VP Paulus Stoffels sold 155,342 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the sale, the vice president now directly owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.19% of the stock is currently owned by insiders.

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after purchasing an additional 3,023,110 shares during the last quarter. BlackRock Inc. raised its stake in Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after purchasing an additional 4,332,612 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Johnson & Johnson by 0.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock valued at $4,757,593,000 after purchasing an additional 130,437 shares during the last quarter. Geode Capital Management LLC raised its stake in Johnson & Johnson by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 30,521,157 shares of the company’s stock valued at $4,256,109,000 after purchasing an additional 939,488 shares during the last quarter. Finally, FMR LLC raised its stake in Johnson & Johnson by 5.9% during the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after purchasing an additional 1,509,745 shares during the last quarter. Institutional investors and hedge funds own 67.35% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2018/03/14/analysts-set-johnson-johnson-jnj-price-target-at-146-02.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.